approval
saveRYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalOct 8, 2025 · 361d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 3, 2025 · 396d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 14, 2025 · 416d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalFeb 14, 2025 · 597d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 19, 2024 · 745d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024 · 776d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalMar 1, 2024 · 947d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 4, 2022 · 1430d ago
same company · ±60 days · 6
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalNov 7, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 6, 2025
- approvalustekinumab: STELARA (USTEKINUMAB) — FDA approvalNov 3, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 14, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 19, 2025
- approvalSIMPONI (GOLIMUMAB) — FDA approvalOct 22, 2025
comments(0)
5-min edit window · permanent after that